Figure 1 from Peripheral Blood IFN Responses to Toll-Like Receptor 1/2 Signaling Associate with Longer Survival in Men with Metastatic Prostate Cancer Treated with Sipuleucel-T

<p>Study design and <i>in vitro</i> responsiveness of PBMCs from patients with mCRPC to PRR agonist prior to sip-T treatment. <b>A,</b> Banked pretreatment PBMCs from the PRIME sip-T discovery cohort (<i>n</i> = 106) or KCI validation cohort (<i>n</i> = 28) were subjected to DNA isolation, flow cytometry, and/or testing in an <i>in vitro</i> stimulation assay. Two hundred thousand PBMCs per well were plated and treated with no stimulation (mock) or stimulation (stim) with TLR1/2 (PAM₃CSK₄), TLR4 (LPS), MDA5 (Poly I:C-LyoVec), or T-cell [anti (α)-CD3/28 antibodies] after 24 hours of culture. <b>B–D,</b> Supernatant cytokine release was measured after <i>in vitro</i> stimulation. <b>B,</b> Principal component analyses colored by treatment using raw MFI values for each analyte, each data point represents a single patient. <b>C,</b> Box and whisker plots (Boxes: median ± 25%–75% quartiles, whiskers = range) of fold mock MFI values for each cytokine in the PRIME study (<i>n</i> = 106), each data point represents a single patient. <b>D,</b> Heatmaps of log (fold mock control) values are shown for the PRIME and KCI (validation) cohorts; asterisks denote FDR adjusted <i>Q</i> < 0.05 using one sample <i>t</i> test vs. 0 (no induction). MFI, mean fluorescence intensity.</p>

Duke Scholars

Author Michael Brown Neurosurgery, Neuro-Oncology

Author Andrew John Armstrong Medicine, Medical Oncology

Author Michael Dee Gunn Medicine, Cardiology

Author Smita K Nair Surgery, Surgical Sciences